U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H6INO4S
Molecular Weight 351.118
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 7-Iodo-8-hydroxyquinoline-5-sulfonic acid

SMILES

OC1=C(I)C=C(C2=CC=CN=C12)S(O)(=O)=O

InChI

InChIKey=ZBJWWKFMHOAPNS-UHFFFAOYSA-N
InChI=1S/C9H6INO4S/c10-6-4-7(16(13,14)15)5-2-1-3-11-8(5)9(6)12/h1-4,12H,(H,13,14,15)

HIDE SMILES / InChI

Molecular Formula C9H6INO4S
Molecular Weight 351.118
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

8-Hydroxy-7-iodo-5-quinolinesulfonic acid (Ferron) showed fungistatic effect for Candida and for M. canis and T. mentagrophytes. Resotren is a chemical combination of chloroquine and iodohydroxyquinoline and, taken by mouth, is poorly absorbed and reaches the lower bowel in considerable concentration. Resotren is effective in both intestinal and extra-intestinal amoebiasis. Al-Ferron timed spectrophotometry assay is a basic method in the study on the formation of polynuclear hydroxyl aluminum species and their transformation laws in aqueous systems.

Originator

Sources: DOI: 10.1002/ardp.18932310913

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Resotren

Approved Use

Indicated for the treatment of amoebic dysentery, ulcerative colitis, intestinal infections; purulent wounds, ulcers, burns; acute, chronic articular rheumatism and in gynecological and urological practice.
Primary
Unknown

Approved Use

Indicated for the treatment of amoebic dysentery, ulcerative colitis, intestinal infections; purulent wounds, ulcers, burns; acute, chronic articular rheumatism and in gynecological and urological practice.
Primary
Unknown

Approved Use

Indicated for the treatment of amoebic dysentery, ulcerative colitis, intestinal infections; purulent wounds, ulcers, burns; acute, chronic articular rheumatism and in gynecological and urological practice.
PubMed

PubMed

TitleDatePubMed
Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart.
2010-11
Aluminum polymers formed following alum treatment of lake water.
2010-11
Conformational dynamics of actin: effectors and implications for biological function.
2010-10
The N-terminal domain of the arenavirus L protein is an RNA endonuclease essential in mRNA transcription.
2010-09-16
[Comparative study on the coagulation of PACl with different contents of aluminum polymeric species].
2010-08
In the shadow of a new smoke free policy: A discourse analysis of health care providers' engagement in tobacco control in community mental health.
2010-07-28
No bones about it: insulin modulates skeletal remodeling.
2010-07-23
Integrative physiology: defined novel metabolic roles of osteocalcin.
2010-07
Mutation of actin Tyr-53 alters the conformations of the DNase I-binding loop and the nucleotide-binding cleft.
2010-03-26
Using small-scale studies to prioritize threats and guide recovery of a rare hemiparasitic plant: Cordylanthus rigidus ssp. littoralis.
2010-01-26
Grand challenges in bone endocrinology.
2010
Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine.
2010
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project.
2010
Visfatin/PBEF/Nampt: A New Cardiovascular Target?
2010
Low HDL Cholesterol is Associated with Lower Gray Matter Volume in Cognitively Healthy Adults.
2010
Characterization of hydrolyzed Fe(III) species produced in Fenton's reaction.
2009-12-14
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
2009-12-03
Transmembrane AMPA receptor regulatory proteins and AMPA receptor function in the cerebellum.
2009-09-01
k-Value-based ferron assay and its application.
2009-07-01
Study on the hydrolysis/precipitation behavior of Keggin Al13 and Al30 polymers in polyaluminum solutions.
2009-06
Ethnicity and incidence of Hodgkin lymphoma in Canadian population.
2009-05-11
Clustering of cancer among families of cases with Hodgkin Lymphoma (HL), Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), Soft Tissue Sarcoma (STS) and control subjects.
2009-02-27
Comparison of coagulation behavior and floc structure characteristic of different polyferric-cationic polymer dual-coagulants in humic acid solution.
2009-02
Preparation of high concentration polyaluminum chloride with high content of Alb or Alc.
2009
Hydrolysis and coagulation behavior of polyferric sulfate and ferric sulfate.
2009
Modified ferron assay for speciation characterization of hydrolyzed Al(III): a precise k value based judgment.
2009
Effect of vitamin K supplementation on insulin resistance in older men and women.
2008-11
Impaired leukocyte influx in cervix of postterm women not responding to prostaglandin priming.
2008-09-02
[Al species distribution of organic silicate aluminum hybrid flocculants by Al-ferron complexation timed spectrophotometric method].
2008-09
Model for the deposition of aerosol particles in the respiratory tract of the rat. I. Nonhygroscopic particle deposition.
2008-09
Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees.
2008-09
Occupational exposures and non-Hodgkin's lymphoma: Canadian case-control study.
2008-08-07
Wake up and smell the coffee: yet another no go for cardiac patients? : editorial to "caffeinated coffee blunts the myocardial protective effects of statins against ischemia-reperfusion injury in the rat" by Ye et al.
2008-08
The novel adipocytokine visfatin exerts direct cardioprotective effects.
2008-08
OnD-CRF: predicting order and disorder in proteins using [corrected] conditional random fields.
2008-06-01
3-Amino-pyridinium 4-hydr-oxy-3-iodo-naphthalene-1-sulfonate dihydrate.
2008-05-17
Enhanced coagulation with polyaluminum chlorides: role of pH/alkalinity and speciation.
2008-04
Glucose-insulin therapy, plasma substrate levels and cardiac recovery after cardiac ischemic events.
2008-04
Relative importance of hydrolyzed Al(III) species (Al(a), Al(b), and Al(c)) during coagulation with polyaluminum chloride: a case study with the typical micro-polluted source waters.
2007-12-15
Highly selective and sensitized spectrophotometric determination of iron (III) following potentiometric study.
2007-09
Proton-transfer compounds of 8-hydroxy-7-iodoquinoline-5-sulfonic acid (ferron) with 4-chloroaniline and 4-bromoaniline.
2007-07
Simulation of developmental changes in action potentials with ventricular cell models.
2007-03
A generalized analysis of hydrophobic and loop clusters within globular protein sequences.
2007-01-08
Ischemic preconditioning: protection against myocardial necrosis and apoptosis.
2007
Analytical methods for PCBs and organochlorine pesticides in environmental monitoring and surveillance: a critical appraisal.
2006-10
Al(III) speciation distribution and transformation in high concentration PACl solutions.
2006
The modeled structure of the RNA dependent RNA polymerase of GBV-C virus suggests a role for motif E in Flaviviridae RNA polymerases.
2005-10-14
Effect of citric acid on aluminum hydrolytic speciation.
2005-09
Migration and mental health in Europe (the state of the mental health in Europe working group: appendix 1).
2005-08-31
Dual emission probe for luminescence oxygen sensing: a critical comparison between intensity, lifetime and ratiometric measurements.
2005-04-30
Patents

Sample Use Guides

Usually a course of resotren consisted of 40 tablets given as follows: 1st day - 3x2 tablet=6 2nd-5th day - 4x1 tablet=16 6th-10th day - 3x1 tablet=15 11th-12th day - 3x0.5 tablet=3 resotren tablet contains 0.5 g of cloquinate
Route of Administration: Oral
8-hydroxy-7-iodo-5-quinolinesulfonic acid demonstrated MIC50 for Candid glabrata and C.krusei is 16 ug/ml but for C.albicans, C.parapsilosis and C.tropicals is 64 ug/ml.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:00:21 GMT 2025
Edited
by admin
on Mon Mar 31 19:00:21 GMT 2025
Record UNII
6E8Y02XFEI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
7-Iodo-8-hydroxyquinoline-5-sulfonic acid
Systematic Name English
8-Hydroxy-7-iodo-5-quinolinesulfonic acid
MI  
Preferred Name English
7-IODOOXINE-5-SULFONIC ACID
Common Name English
NSC-3784
Code English
8-hydroxy-7-iodo-5-quinioline sulfonic acid [WHO-DD]
Common Name English
8-HYDROXY-7-IODO-5-QUINOLINESULFONIC ACID [MI]
Common Name English
M-IODO-O-HYDROXYQUINOLINEANASULFONIC ACID
Common Name English
5-Quinolinesulfonic acid, 8-hydroxy-7-iodo-
Common Name English
Code System Code Type Description
DRUG CENTRAL
3287
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
MERCK INDEX
m6135
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY Merck Index
SMS_ID
100000138957
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
NSC
3784
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
CAS
547-91-1
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
FDA UNII
6E8Y02XFEI
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
EVMPD
SUB13083MIG
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
ALTERNATIVE
MESH
C002833
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
ECHA (EC/EINECS)
208-938-4
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
EPA CompTox
DTXSID1046136
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
PUBCHEM
11043
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
EVMPD
SUB79514
Created by admin on Mon Mar 31 19:00:21 GMT 2025 , Edited by admin on Mon Mar 31 19:00:21 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT